REJECTING a petition of the defendants in the Dengvaxia cases, the Court of Appeals (CA) has affirmed the ruling of four Quezon City Regional Trial Court (QC-RTC) judges who all agreed to consolidate ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Assetmark Inc. raised its stake in shares of Sanofi by 9.8% in the third quarter. Assetmark Inc. now owns 109,375 shares of the company’s stock valued at $6,303,000 after buying an additional ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Saudi Arabia Pharmaceutical Drugs Market is estimated to be valued at US$ 12.60 billion in 2024 and is expected to exhibit a CAGR of 7.6% by 2031 BURLINGAME, CA, UNITED STATES, November 12, 2024 ...